1179 related articles for article (PubMed ID: 14695828)
1. Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents.
Campiani G; Butini S; Fattorusso C; Catalanotti B; Gemma S; Nacci V; Morelli E; Cagnotto A; Mereghetti I; Mennini T; Carli M; Minetti P; Di Cesare MA; Mastroianni D; Scafetta N; Galletti B; Stasi MA; Castorina M; Pacifici L; Vertechy M; Di Serio S; Ghirardi O; Tinti O; Carminati P
J Med Chem; 2004 Jan; 47(1):143-57. PubMed ID: 14695828
[TBL] [Abstract][Full Text] [Related]
2. New antipsychotic agents with serotonin and dopamine antagonist properties based on a pyrrolo[2,1-b][1,3]benzothiazepine structure.
Campiani G; Nacci V; Bechelli S; Ciani SM; Garofalo A; Fiorini I; Wikström H; de Boer P; Liao Y; Tepper PG; Cagnotto A; Mennini T
J Med Chem; 1998 Sep; 41(20):3763-72. PubMed ID: 9748351
[TBL] [Abstract][Full Text] [Related]
3. Pyrrolo[1,3]benzothiazepine-based atypical antipsychotic agents. Synthesis, structure-activity relationship, molecular modeling, and biological studies.
Campiani G; Butini S; Gemma S; Nacci V; Fattorusso C; Catalanotti B; Giorgi G; Cagnotto A; Goegan M; Mennini T; Minetti P; Di Cesare MA; Mastroianni D; Scafetta N; Galletti B; Stasi MA; Castorina M; Pacifici L; Ghirardi O; Tinti O; Carminati P
J Med Chem; 2002 Jan; 45(2):344-59. PubMed ID: 11784139
[TBL] [Abstract][Full Text] [Related]
4. Novel atypical antipsychotic agents: rational design, an efficient palladium-catalyzed route, and pharmacological studies.
Campiani G; Butini S; Fattorusso C; Trotta F; Gemma S; Catalanotti B; Nacci V; Fiorini I; Cagnotto A; Mereghetti I; Mennini T; Minetti P; Di Cesare MA; Stasi MA; Di Serio S; Ghirardi O; Tinti O; Carminati P
J Med Chem; 2005 Mar; 48(6):1705-8. PubMed ID: 15771414
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and structure-affinity relationships of novel N-(1-ethyl-4-methylhexahydro-1,4-diazepin-6-yl)pyridine-3-carboxamides with potent serotonin 5-HT3 and dopamine D2 receptor antagonistic activity.
Hirokawa Y; Fujiwara I; Suzuki K; Harada H; Yoshikawa T; Yoshida N; Kato S
J Med Chem; 2003 Feb; 46(5):702-15. PubMed ID: 12593651
[TBL] [Abstract][Full Text] [Related]
6. New (sulfonyloxy)piperazinyldibenzazepines as potential atypical antipsychotics: chemistry and pharmacological evaluation.
Liao Y; Venhuis BJ; Rodenhuis N; Timmerman W; Wikström H; Meier E; Bartoszyk GD; Böttcher H; Seyfried CA; Sundell S
J Med Chem; 1999 Jun; 42(12):2235-44. PubMed ID: 10377229
[TBL] [Abstract][Full Text] [Related]
7. S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: I. Receptor-binding profile and functional actions at G-protein-coupled receptors.
Millan MJ; Mannoury la Cour C; Novi F; Maggio R; Audinot V; Newman-Tancredi A; Cussac D; Pasteau V; Boutin JA; Dubuffet T; Lavielle G
J Pharmacol Exp Ther; 2008 Feb; 324(2):587-99. PubMed ID: 18024789
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo characterization of F-97013-GD, a partial 5-HT1A agonist with antipsychotic- and antiparkinsonian-like properties.
Zazpe A; Artaiz I; Innerárity A; Del Olmo E; Castro E; Labeaga L; Pazos A; Orjales A
Neuropharmacology; 2006 Jul; 51(1):129-40. PubMed ID: 16643965
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular characterization of pyrrolo[2,1-d][1,5]benzothiazepine derivatives binding selectively to the peripheral-type benzodiazepine receptor (PBR): from dual PBR affinity and calcium antagonist activity to novel and selective calcium entry blockers.
Campiani G; Fiorini I; De Filippis MP; Ciani SM; Garofalo A; Nacci V; Giorgi G; Sega A; Botta M; Chiarini A; Budriesi R; Bruni G; Romeo MR; Manzoni C; Mennini T
J Med Chem; 1996 Jul; 39(15):2922-38. PubMed ID: 8709127
[TBL] [Abstract][Full Text] [Related]
10. KKHA-761, a potent D3 receptor antagonist with high 5-HT1A receptor affinity, exhibits antipsychotic properties in animal models of schizophrenia.
Park WK; Jeong D; Cho H; Lee SJ; Cha MY; Pae AN; Choi KI; Koh HY; Kong JY
Pharmacol Biochem Behav; 2005 Oct; 82(2):361-72. PubMed ID: 16216322
[TBL] [Abstract][Full Text] [Related]
11. Serotonin 5-HT2 receptor, dopamine D2 receptor, and alpha 1 adrenoceptor antagonists. Conformationally flexible analogues of the atypical antipsychotic sertindole.
Andersen K; Liljefors T; Hyttel J; Perregaard J
J Med Chem; 1996 Sep; 39(19):3723-38. PubMed ID: 8809161
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and pharmacological evaluation of potent and highly selective D3 receptor ligands: inhibition of cocaine-seeking behavior and the role of dopamine D3/D2 receptors.
Campiani G; Butini S; Trotta F; Fattorusso C; Catalanotti B; Aiello F; Gemma S; Nacci V; Novellino E; Stark JA; Cagnotto A; Fumagalli E; Carnovali F; Cervo L; Mennini T
J Med Chem; 2003 Aug; 46(18):3822-39. PubMed ID: 12930145
[TBL] [Abstract][Full Text] [Related]
13. The atypical antipsychotic profile of NRA0045, a novel dopamine D4 and 5-hydroxytryptamine2A receptor antagonist, in rats.
Okuyama S; Chaki S; Kawashima N; Suzuki Y; Ogawa S; Kumagai T; Nakazato A; Nagamine M; Yamaguchi K; Tomisawa K
Br J Pharmacol; 1997 Jun; 121(3):515-25. PubMed ID: 9179395
[TBL] [Abstract][Full Text] [Related]
14. Discovery of a new class of potential multifunctional atypical antipsychotic agents targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors: design, synthesis, and effects on behavior.
Butini S; Gemma S; Campiani G; Franceschini S; Trotta F; Borriello M; Ceres N; Ros S; Coccone SS; Bernetti M; De Angelis M; Brindisi M; Nacci V; Fiorini I; Novellino E; Cagnotto A; Mennini T; Sandager-Nielsen K; Andreasen JT; Scheel-Kruger J; Mikkelsen JD; Fattorusso C
J Med Chem; 2009 Jan; 52(1):151-69. PubMed ID: 19072656
[TBL] [Abstract][Full Text] [Related]
15. Long-term effects of JL 13, a potential atypical antipsychotic, on rat dopamine and serotonin receptor subtypes.
Moran-Gates T; Massari C; Graulich A; Liégeois JF; Tarazi FI
J Neurosci Res; 2006 Aug; 84(3):675-82. PubMed ID: 16810690
[TBL] [Abstract][Full Text] [Related]
16. Novel sulfonamides having dual dopamine D2 and D3 receptor affinity show in vivo antipsychotic efficacy with beneficial cognitive and EPS profile.
Agai-Csongor E; Nógrádi K; Galambos J; Vágó I; Bielik A; Magdó I; Ignácz-Szendrei G; Keseru GM; Greiner I; Laszlovszky I; Schmidt E; Kiss B; Sághy K; Laszy J; Gyertyán I; Zájer-Balázs M; Gémesi L; Domány G
Bioorg Med Chem Lett; 2007 Oct; 17(19):5340-4. PubMed ID: 17720494
[TBL] [Abstract][Full Text] [Related]
17. L-745,870, a subtype selective dopamine D4 receptor antagonist, does not exhibit a neuroleptic-like profile in rodent behavioral tests.
Bristow LJ; Collinson N; Cook GP; Curtis N; Freedman SB; Kulagowski JJ; Leeson PD; Patel S; Ragan CI; Ridgill M; Saywell KL; Tricklebank MD
J Pharmacol Exp Ther; 1997 Dec; 283(3):1256-63. PubMed ID: 9400001
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological profile of SCH39166: a dopamine D1 selective benzonaphthazepine with potential antipsychotic activity.
Chipkin RE; Iorio LC; Coffin VL; McQuade RD; Berger JG; Barnett A
J Pharmacol Exp Ther; 1988 Dec; 247(3):1093-102. PubMed ID: 2905002
[TBL] [Abstract][Full Text] [Related]
19. Dopamine D3 and D4 receptor antagonists: synthesis and structure--activity relationships of (S)-(+)-N-(1-Benzyl-3-pyrrolidinyl)-5-chloro-4- [(cyclopropylcarbonyl) amino]-2-methoxybenzamide (YM-43611) and related compounds.
Ohmori J; Maeno K; Hidaka K; Nakato K; Matsumoto M; Tada S; Hattori H; Sakamoto S; Tsukamoto S; Usuda S; Mase T
J Med Chem; 1996 Jul; 39(14):2764-72. PubMed ID: 8709107
[TBL] [Abstract][Full Text] [Related]
20. S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)- and alpha(2)-adrenergic receptors: II. Functional profile and a multiparametric comparison with haloperidol, clozapine, and 11 other antipsychotic agents.
Millan MJ; Brocco M; Rivet JM; Audinot V; Newman-Tancredi A; Maiofiss L; Queriaux S; Despaux N; Peglion JL; Dekeyne A
J Pharmacol Exp Ther; 2000 Jan; 292(1):54-66. PubMed ID: 10604931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
